跨性别者接受激素治疗的乳腺癌风险:荷兰全国队列研究
该回顾性全国队列研究纳入2260名跨性别女性和1229名跨性别男性,均接受性别肯定激素治疗。跨性别女性乳腺癌发病率较顺性别男性高46倍但低于顺性别女性,跨性别男性则低于顺性别女性;肿瘤特征在跨性别女性中更接近女性模式。结果提示现有顺性别人群乳腺癌筛查指南对接受激素治疗的跨性别者可能足够。
要点
- 跨性别女性乳腺癌风险显著高于顺性别男性,但低于顺性别女性。
- 跨性别男性乳腺癌风险低于顺性别女性。
- 跨性别女性乳腺癌多在较短激素治疗时间内出现,特征偏女性型。
核心结论
- 跨性别女性接受激素治疗后乳腺癌风险较顺性别男性增加,但低于顺性别女性。
- 跨性别男性乳腺癌风险低于顺性别女性。
- 跨性别女性乳腺癌特征更接近女性模式,现有顺性别筛查指南可能足够。
研究设计与样本
- 回顾性全国队列研究,纳入2260名跨性别女性和1229名跨性别男性,均接受性别肯定激素治疗。
- 设置:荷兰阿姆斯特丹专门三级性别诊所。
主要发现
- 跨性别女性中识别15例浸润性乳腺癌,激素治疗中位时长18年(范围7-37年)。
- 跨性别女性乳腺癌标准化发病比46.7(95%CI 27.2-75.4),高于顺性别男性;相比顺性别女性为0.3(95%CI 0.2-0.4),低于顺性别女性。
- 跨性别女性肿瘤多为导管来源、雌激素和孕激素受体阳性,8.3%为HER2阳性。
- 跨性别男性中识别4例浸润性乳腺癌,激素治疗中位时长15年(范围2-17年)。
- 跨性别男性乳腺癌标准化发病比0.2(95%CI 0.1-0.5),低于顺性别女性。
临床怎么用
- 对接受激素治疗的跨性别女性应关注乳腺癌风险,可参考顺性别女性筛查指南进行筛查。
- 跨性别男性乳腺癌风险低于顺性别女性,筛查策略可参考现有指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the incidence and characteristics of breast cancer in transgender people in the Netherlands compared with the general Dutch population. DESIGN: Retrospective, nationwide cohort study. SETTING: Specialised tertiary gender clinic in Amsterdam, the Netherlands. PARTICIPANTS: 2260 adult trans women (male sex assigned at birth, female gender identity) and 1229 adult trans men (female sex assigned at birth, male gender identity) who received gender affirming hormone treatment. MAIN OUTCOME MEASURES: Incidence and characteristics (eg, histology, hormone receptor status) of breast cancer in transgender people. RESULTS: The total person time in this cohort was 33 991 years for trans women and 14 883 years for trans men. In the 2260 trans women in the cohort, 15 cases of invasive breast cancer were identified (median duration of hormone treatment 18 years, range 7-37 years). This was 46-fold higher than in cisgender men (standardised incidence ratio 46.7, 95% confidence interval 27.2 to 75.4) but lower than in cisgender women (0.3, 0.2 to 0.4). Most tumours were of ductal origin and oestrogen and progesterone receptor positive, and 8.3% were human epidermal growth factor 2 (HER2) positive. In 1229 trans men, four cases of invasive breast cancer were identified (median duration of hormone treatment 15 years, range 2-17 years). This was lower than expected compared with cisgender women (standardised incidence ratio 0.2, 95% confidence interval 0.1 to 0.5). CONCLUSIONS: This study showed an increased risk of breast cancer in trans women compared with cisgender men, and a lower risk in trans men compared with cisgender women. In trans women, the risk of breast cancer increased during a relatively short duration of hormone treatment and the characteristics of the breast cancer resembled a more female pattern. These results suggest that breast cancer screening guidelines for cisgender people are sufficient for transgender people using hormone treatment.
引用
- de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ. 2019. PMID: 31088823. doi:10.1136/bmj.l1652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。